423 related articles for article (PubMed ID: 30181581)
41. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
42. New development in CAR-T cell therapy.
Wang Z; Wu Z; Liu Y; Han W
J Hematol Oncol; 2017 Feb; 10(1):53. PubMed ID: 28222796
[TBL] [Abstract][Full Text] [Related]
43. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Santomasso BD; Park JH; Salloum D; Riviere I; Flynn J; Mead E; Halton E; Wang X; Senechal B; Purdon T; Cross JR; Liu H; Vachha B; Chen X; DeAngelis LM; Li D; Bernal Y; Gonen M; Wendel HG; Sadelain M; Brentjens RJ
Cancer Discov; 2018 Aug; 8(8):958-971. PubMed ID: 29880584
[TBL] [Abstract][Full Text] [Related]
44. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
45. Paving the road ahead for CD19 CAR T-cell therapy.
Nellan A; Lee DW
Curr Opin Hematol; 2015 Nov; 22(6):516-20. PubMed ID: 26335422
[TBL] [Abstract][Full Text] [Related]
46. CAR T-cells for relapsed B-cell ALL in adults.
Gilbert JA
Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
[No Abstract] [Full Text] [Related]
47. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
Schubert ML; Schmitt M; Wang L; Ramos CA; Jordan K; Müller-Tidow C; Dreger P
Ann Oncol; 2021 Jan; 32(1):34-48. PubMed ID: 33098993
[TBL] [Abstract][Full Text] [Related]
48. CAR T-cell therapy-related neurotoxicity in paediatric acute lymphocytic leukaemia.
Tan AP
Pediatr Blood Cancer; 2020 Nov; 67(11):e28635. PubMed ID: 32770654
[TBL] [Abstract][Full Text] [Related]
49. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Kallam A; Vose JM
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
[TBL] [Abstract][Full Text] [Related]
50. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
[TBL] [Abstract][Full Text] [Related]
51. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
52. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
53. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
54. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road.
Gill S; Porter DL
Expert Opin Biol Ther; 2014 Jan; 14(1):37-49. PubMed ID: 24261468
[TBL] [Abstract][Full Text] [Related]
55. Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.
Shalabi H; Wolters PL; Martin S; Toledo-Tamula MA; Roderick MC; Struemph K; Kane E; Yates B; Delbrook C; Mackall CL; Lee DW; Fry TJ; Shah NN
J Immunother; 2018 Sep; 41(7):350-358. PubMed ID: 30048343
[TBL] [Abstract][Full Text] [Related]
56. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.
Obstfeld AE; Frey NV; Mansfield K; Lacey SF; June CH; Porter DL; Melenhorst JJ; Wasik MA
Blood; 2017 Dec; 130(23):2569-2572. PubMed ID: 29074500
[No Abstract] [Full Text] [Related]
57. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Makita S; Yoshimura K; Tobinai K
Cancer Sci; 2017 Jun; 108(6):1109-1118. PubMed ID: 28301076
[TBL] [Abstract][Full Text] [Related]
58. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
59. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
Magee MS; Snook AE
Discov Med; 2014 Nov; 18(100):265-71. PubMed ID: 25425467
[TBL] [Abstract][Full Text] [Related]
60. Adoptive therapy with CAR redirected T cells for hematological malignancies.
Li S; Yang Z; Shen J; Shan J; Qian C
Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
